Last year, the USFDA approved the first fecal microbiota product that can be administered rectally to prevent the recurrence of Clostridioides difficile infection (rCDI) in patients aged 18 years and above. Now, the agency has approved another fecal microbiota product that can be administered orally for the first time to prevent rCDI in adults. Here is a visual abstract describing the orally administered fecal microbiota product for preventing rCDI. Can fecal microbiota products be used to treat GI tract infections?
Share your views by commenting below! Suggested for you Can Gut Bacteria Affect Insulin Homeostasis? Can Gut Microbiome Help Detect Pregnancy Complications Early? Source : FDA
